By Fineline Cube 
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the inclusion of its sunvozertinib (trade name: Zegfrovy) in the U.S. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC). The drug is now recommended for previously treated EGFR exon 20 insertion mutation (exon20ins)-positive NSCLC.
Sunvozertinib’s Approval and Recognition
Sunvozertinib is an oral, irreversible, and highly selective EGFR tyrosine kinase inhibitor (TKI) targeting multiple EGFR mutation subtypes. Earlier this month, it was approved in the US, becoming the first and only China-discovered innovative drug for EGFR exon20ins NSCLC to receive U.S. approval. This milestone also marks it as the first globally to achieve this recognition.
NCCN Guidelines Inclusion
With its inclusion in the NCCN Guidelines, sunvozertinib now stands as the only small-molecule targeted therapy for EGFR exon20ins NSCLC endorsed by an international authoritative lung cancer guideline. This endorsement underscores the drug’s significance in the treatment landscape for this specific patient population.-Fineline Info & Tech